ALT
Price
$5.47
Change
+$1.47 (+36.75%)
Updated
Feb 3 closing price
Capitalization
685.02M
50 days until earnings call
Intraday BUY SELL Signals
KROS
Price
$18.47
Change
+$2.35 (+14.58%)
Updated
Feb 3 closing price
Capitalization
562.71M
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALT vs KROS

Header iconALT vs KROS Comparison
Open Charts ALT vs KROSBanner chart's image
Altimmune
Price$5.47
Change+$1.47 (+36.75%)
Volume$4.57M
Capitalization685.02M
Keros Therapeutics
Price$18.47
Change+$2.35 (+14.58%)
Volume$258.43K
Capitalization562.71M
ALT vs KROS Comparison Chart in %
View a ticker or compare two or three
VS
ALT vs. KROS commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Buy and KROS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (ALT: $5.47 vs. KROS: $18.47)
Brand notoriety: ALT and KROS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 81% vs. KROS: 48%
Market capitalization -- ALT: $685.02M vs. KROS: $562.71M
ALT [@Biotechnology] is valued at $685.02M. KROS’s [@Biotechnology] market capitalization is $562.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileKROS’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • KROS’s FA Score: 0 green, 5 red.
According to our system of comparison, KROS is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 7 TA indicator(s) are bullish while KROS’s TA Score has 5 bullish TA indicator(s).

  • ALT’s TA Score: 7 bullish, 4 bearish.
  • KROS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ALT is a better buy in the short-term than KROS.

Price Growth

ALT (@Biotechnology) experienced а -11.49% price change this week, while KROS (@Biotechnology) price change was +0.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.

Reported Earning Dates

ALT is expected to report earnings on Mar 26, 2026.

KROS is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($685M) has a higher market cap than KROS($563M). ALT YTD gains are higher at: 51.524 vs. KROS (-9.283). KROS has higher annual earnings (EBITDA): 68.8M vs. ALT (-83.72M). KROS has more cash in the bank: 693M vs. ALT (211M). ALT has less debt than KROS: ALT (15.9M) vs KROS (17.4M). KROS has higher revenues than ALT: KROS (247M) vs ALT (20K).
ALTKROSALT / KROS
Capitalization685M563M122%
EBITDA-83.72M68.8M-122%
Gain YTD51.524-9.283-555%
P/E RatioN/A11.84-
Revenue20K247M0%
Total Cash211M693M30%
Total Debt15.9M17.4M91%
FUNDAMENTALS RATINGS
ALT vs KROS: Fundamental Ratings
ALT
KROS
OUTLOOK RATING
1..100
1765
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9769
PRICE GROWTH RATING
1..100
3744
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KROS's Valuation (59) in the null industry is somewhat better than the same rating for ALT (96) in the Miscellaneous Commercial Services industry. This means that KROS’s stock grew somewhat faster than ALT’s over the last 12 months.

KROS's Profit vs Risk Rating (100) in the null industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that KROS’s stock grew similarly to ALT’s over the last 12 months.

KROS's SMR Rating (69) in the null industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that KROS’s stock grew similarly to ALT’s over the last 12 months.

ALT's Price Growth Rating (37) in the Miscellaneous Commercial Services industry is in the same range as KROS (44) in the null industry. This means that ALT’s stock grew similarly to KROS’s over the last 12 months.

KROS's P/E Growth Rating (99) in the null industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that KROS’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTKROS
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 8 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signal:
Gain/Loss:
KROS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SPMAX10.110.10
+1.00%
Saratoga Mid Capitalization A
THOFX51.650.47
+0.92%
Thornburg Global Opportunities R5
KGDAX31.900.23
+0.73%
DWS Global Small Cap A
FTAWX14.53N/A
N/A
Fidelity Advisor Asset Manager 20% A
JRSAX12.34-0.13
-1.04%
JH Adaptive Risk Mgd U.S. Eq A

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with INDP. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then INDP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
-1.44%
INDP - ALT
45%
Loosely correlated
-7.96%
ACHV - ALT
44%
Loosely correlated
-2.56%
KROS - ALT
39%
Loosely correlated
+0.38%
AMRN - ALT
38%
Loosely correlated
+0.37%
RXRX - ALT
35%
Loosely correlated
-1.91%
More

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+0.38%
INO - KROS
53%
Loosely correlated
-0.59%
AXON - KROS
43%
Loosely correlated
-1.89%
CLDX - KROS
41%
Loosely correlated
+2.07%
ALT - KROS
39%
Loosely correlated
-1.44%
SPHDF - KROS
38%
Loosely correlated
N/A
More